Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematological Diseases, Non-MalignantHematologic NeoplasmsProtocol groupAcute LeukemiasAnemias, CytopeniasMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)TransplantationDiseaseAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic NeoplasmsStem Cell Transplantation, AllogeneicSubgroupDeletion (5q)High riskLow riskwith Ring SideroblastsICD10C92.0-C92.5-C92.6-C92.7-C92.8-C92.9-C93.0-C93.1-D46.-MeSHLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMyelodysplastic SyndromesSequenceChemotherapyChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanChemo-substanceAzacitidineCytarabineDecitabineDecitabine-CedazuridineGlasdegibLenalidomideMelphalanNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleSupportive substanceAciclovirAnti-thymocyte Globulin (Equine)Balanced Crystalloid SolutionCiclosporin ACiprofloxacinCotrimoxazoleDarbepoetinDimetindenEltrombopagEpoetin alfaFilgrastimGranisetronLuspaterceptMethylprednisoloneParacetamolPosaconazoleNo. Substances12310Protocol classificationTherapy classificationalternativecurrent standardIntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapyseveral possibleTherapy phaseTherapy intentioncurative or palliativedisease controlpalliativesupportiveRisksAnemia Hb below 8g/dlAstheniaBleedingColitisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHeart FailureHemorrhageHepatotoxicityHyperbilirubinemiaHypertensionIncrease AminotransferasesInfectionsLeukopeniaNeutropeniaPainParesthesiaPneumoniaPyrexiaRashRenal FailureSepsisThrombocytopenia below 50 000/µlThromboembolic EventUpper Respiratory Tract Infection only studiesPublicationAuthorCortes JECraddock CDíez-Campelo MFenaux PGarcia-Manero GGreenberg PHellström-Lindberg ELübbert MMannone LOliva EN Passweg JRPlatzbecker USasaki KSchroeder TStasi RSteensma DStratmann JVillegas ADiseaseAML- oder CMML-Rezidiv nach allogener StammzelltranplantationAML- oder MDS-Rezidiv nach allogener StammzelltranplantationAML oder Hochrisiko MDS, nicht für eine Standard-Induktionschemotherapie geeignet, ECOG 0-2de-novo oder sekundäre AML, mindestens 1 nicht-kurative Vortherapie, über 65 JahreDe novo oder sekundäres myelodyplastisches Syndrom, alle Risikogruppen, ECOG 0-2Drohendes AML- oder MDS-Rezidiv nach allogener Stammzelltranplantation (Spenderchimärismus <80%)Hochrisiko myelodysplastisches Syndrom, ECOG 0-2Intermediär-1 und -2-Risiko oder Hochrisiko MDS, Alter > 60 Jahre, ECOG 0-2MDS, Niedrig- oder Intermediär-1-Risiko, Deletion an Chromosom 5q, Anämie ohne TransfusionindikationMyelodysplastisches Syndrom, Niedrig-/Intermediär-1-Risiko, Thrombozytenwert unter 30.000/μl, ECOG 0-3Myelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/mlMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, Hgb <10 g/dL, niedrige TransfusionsrateMyelodysplastisches Syndrom, niedriges - intermediäres Risiko, Epo < 500 mU/ml, niedrige Transfusionsrate, ECOG 0-1Myelodysplastisches Syndrom, Niedrigrisiko, ECOG 0-2Myelodysplastisches Syndrom mit refraktärer Anämie mit/ohne Sideroblasten, RAEB-I, oder hypoplastisch, ECOG 0-2Myelodysplastisches Syndrom und chronische myelomonozytäre Leukämie, ECOG 0-2Niedrig- oder Intermediär-1-Risiko, singuläre Deletion an Chromosom 5q, transfusionspflichtige Anämieprimäres myelodysplastisches Syndrom länger als 6 Monate, nicht-transfundierter Hämoglobinwert < 10 g/dl, ECOG 0-2refraktäre Anämie, mit Sideroblasten oder exzessiven Blasten, nichtproliferative CMLrefraktäre Anämie beim myelodysplastischen Syndrom, niedrig-intermediäres Risiko, Epo < 500 mU/ml, niedrige TransfusionsrateTansfusionsabhängige Anämie bei MDS mit Ringsideroblasten, sehr niedriges, niedriges oder intermediäres Risiko nach IPSS-R, kein Ansprechen auf Erythropoetinbasierte Therapie oder nicht dafür geeignet OriginAlbert Ludwigs Universität, Freiburg, deutsche MDS- StudiengruppeARCADE trialAzienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy, EQoL-MDS trialCarl Gustav Carus Technical University of Dresden, Dresden, Germany, RELAZA trialDepartment of Haematology, Nice University Hospital, Groupe Francais des Myelodysplasies (GFM)Department of Hematology, Huddinge University Hospital, Huddinge, SwedenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, HoustonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TXDepartment of Medical Sciences, Regina Apostolorum Hospital, Albano LazialeDivision Hematology and Oncology, University of Freiburg Medical Center, Freiburg, GermanyHematology and Oncology, Goethe University, Frankfurt, Frankfurt am Main, GermanyHematology Department, Hospital Clinico San Carlos, Madrid, SpanienHopital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris XIII, Bobigny, FranceHopital Saint-Louis, Assistance Publique-Hopitaux de Paris and Universite Paris 7, Paris, FranceHopitaux Universitaires de Geneve, Geneva, SAKK 33/99Hospital Universitario de Salamanca, Salamanca, Spain, SintraREV trialMayo Clinic Rochester, MN; Roswell Park Cancer Institute, Buffalo, NY, ADOPT trialOncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Duesseldorf, GermanyService d´Hematologie Clinique, Hoptial, Avicenne/Universite Paris, FranceStanford University Cancer Center, CA (ECOG E1996)University of Birmingham, Birmingham, United KingdomUniversity of Texas, MD Anderson Cancer Center, Houston, USAProtocols in Revision 23 protocols foundProtocols under revision.Anti-thymocyte Globulin (Equine) 15 / Ciclosporin 5, Myelodysplastic Syndrome. (PID1766 V1.2)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID2302 V1.0)Azacitidine 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation, Variant 1. (PID2320 V1.0)Azacitidine 75 / Lenalidomide 25, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation (PID827 V1.2)Azacitidine 75, Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplantation. (PID2327 V1.0)Azacitidine 75, Myelodysplastic Syndrome, High-Risk (PID616 V1.0)Azacitidine 75, Myelodysplastic Syndrome, Low risk (PID2317 V1.0)Cytarabine 20 / Glasdegib 100, Acute Myeloid Leukemia and Myelodysplastic Syndrome (PID1674 V1.0)Darbepoetin alfa 150, Myelodysplastic Syndrome (PID783 V1.0)Darbepoetin alfa 300 / Filgrastim 300, Myelodysplastic Syndrome (PID838 V1.0)Darbepoetin alfa 300, Myelodysplastic Syndrome (PID836 V1.0)Darbepoetin alfa 500, Myelodysplastic Syndrome (PID837 V1.0)Decitabine 15, Myelodysplastic Syndrome (PID727 V1.0)Decitabine 20, Myelodysplastic Syndrome (PID904 V1.0)Decitabine 20, Myelodysplastic Syndrome, Low risk (PID2318 V1.0)Decitabine-Cedazuridine 135, Myelodysplastic Syndrome (PID2514 V1.0)Eltrombopag 50, Myelodysplastic Syndrome (PID2513 V1.0)Epoetin Alfa 40000 / Filgrastim 120, Myelodysplastic Syndrome (PID728 V1.1)Epoetin Alfa 40000, Myelodysplastic Syndrome (PID841 V1.0)Lenalidomide 10, Myelodysplastic Syndrome (PID118 V1.1)Lenalidomide 5, Myelodysplastic Syndrome (PID2700 V1.0)Luspatercept 1.0, Myelodysplastic Syndrome (PID1603 V1.0)Melphalan 2, Acute Myeloid Leukemia, over 65 years of age (PID1735 V1.1)
